Spontaneous Tumor Model for Drug Efficacy Research

Increase the predictivity of drug discovery

HOW IT WORKS

Companion animals can be used as a informative model in the preclinical development and discovery of novel cancer treatment.
 
Studies in dogs provide guidance for conducting similar investigation in human patients.
This model helps to evaluate the efficacy  and feasibility of new compounds and can inform the GO/NO-GO decision in clinical drug development.

Selected compound with anti-cancer activity demonstrated in vitro and mice studies 

We design and conduct 

companion animals trials in

our veterinary international

practices network

High predictivity

efficacy results

Go/No-Go Decision

Examples of Preclinical Investigation in Companion Animals 

Acalabrutinib

FDA approved for human use

Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).

Hydroxychloroquine

Phase II human trial completed

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure.

Ibrutinib

FDA approved for human use

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.

Ganetespib

Phase III human trials

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity

NHS-IL12

Phase I human trials ongoing

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Sulphonamide PAC-1 or SPAC-1

Human trials were not conducted

Decision was made to not move forward with human studies based on companion animals trials results.

https://www.ncbi.nlm.nih.gov/books/NBK338437/

PAC-1

Phase I human trials ongoing

Assessed single-agent activity and toxicity for development of tolerable dosing regimen.

KPT-335

Phase I human trials ongoing

Determined dosing regimen and supportive care protocols in companion animals. Identified adverse events, dose, and regimen.

LMP400, LMP776 and LMP744

Phase I human trials ongoing

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.

Masitinib

Phase III human trials ongoing

Studies in companion animals confirmed inhibition and tumor response. Important proof of concept study. Masitinib is EMA-approved for veterinary use.

Are you having problem to translate results from mice to human?

 
Less than 8% of compounds tested in mice models pass successfully human phase I clinical trial
Learn how our In vivo Efficacy Model for Cancer Research can increase the predictivity of drug discovery

 
 

Get in touch

Company Team

 

Lucas Rodrigues, DVM, MS, PhD

CEO & Scientific Director

lrodrigues@ridgeresearch.us

Mauricio Bauer, DVM, BVSc.,MBA

mbauer@ridgeresearch.us

 

Francisco Scacchetti, BBA

Chief Financial Officer

Bruce Truman

Strategic Adviser

btruman@bltconsulting.com

Contact

contact@ridgeresearch.us

Office

505 S. Rosa Road, Suite 225

Madison, WI 53719

© RIDGE RESEARCH 2016-2019